Mandate

Vinge has advised the arrangers in connection with Heimstaden’s EUR 350,000,000 bond issuance

The banks acted as arrangers and bookrunners in connection with Heimstaden AB’s (publ) issuance of EUR 350,000,000 senior unsecured bonds, within a framework amount of EUR 450,000,000.

The bond proceeds are intended to be used for the purchase of equity in Heimstaden Bostad AB and general corporate purposes. In accordance with the terms and conditions, the bonds are intended to be listed on the corporate bond list of Nasdaq Stockholm.

Vinge’s team consisted of Louise Brorsson Salomon and Lionardo Ojeda (Banking and Finance) together with Jesper Schönbeck and Linnéa Sellström (Capital Markets and Public M&A).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026